Patients with psoriasis have a higher risk of dementia: A systematic review and meta-analysis.
Dementia
meta-analysis
psoriasis
Journal
Indian journal of dermatology, venereology and leprology
ISSN: 0973-3922
Titre abrégé: Indian J Dermatol Venereol Leprol
Pays: United States
ID NLM: 7701852
Informations de publication
Date de publication:
Historique:
received:
01
08
2019
accepted:
01
01
2020
pubmed:
6
3
2021
medline:
11
11
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
Patients with psoriasis may have a higher risk of dementia because of the higher inflammatory burden, although results from previous epidemiological studies have been inconsistent. To determine the association between psoriasis and risk of dementia by pooling the evidence from previous studies. Potentially eligible studies were identified from Medline and EMBASE databases from inception to July 2019 using a search that comprised terms for "psoriasis" and "dementia." Studies were eligible for the meta-analysis if they were cohort studies that included psoriatic patients and individuals without psoriasis and followed them for incident dementia. Studies were also required to report standardized incidence ratio, hazard risk ratio or relative risk with related 95% confidence intervals (CI) comparing the incidence of dementia between the two cohorts. The retrieved point estimates with standard errors from each study were pooled into the final result by the random-effect model, generic inverse variance method. A total of 8,861 articles were identified. After two rounds of independent review by three investigators, we included six cohort studies that met the eligibility criteria in the meta-analysis. The risk of dementia was significantly higher among psoriatic patients than in those without psoriasis with a pooled risk ratio of 1.16 (95% CI, 1.04-1.30; I2 95%). A funnel plot was relatively symmetric and was not suggestive of the presence of publication bias. Limited accuracy of diagnosis of psoriasis and dementia as four included studies were coding-based studies, and high statistical heterogeneity among studies. This systematic review and meta-analysis indicates that psoriatic patients have a significantly elevated risk of developing dementia.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with psoriasis may have a higher risk of dementia because of the higher inflammatory burden, although results from previous epidemiological studies have been inconsistent.
AIMS
OBJECTIVE
To determine the association between psoriasis and risk of dementia by pooling the evidence from previous studies.
METHODS
METHODS
Potentially eligible studies were identified from Medline and EMBASE databases from inception to July 2019 using a search that comprised terms for "psoriasis" and "dementia." Studies were eligible for the meta-analysis if they were cohort studies that included psoriatic patients and individuals without psoriasis and followed them for incident dementia. Studies were also required to report standardized incidence ratio, hazard risk ratio or relative risk with related 95% confidence intervals (CI) comparing the incidence of dementia between the two cohorts. The retrieved point estimates with standard errors from each study were pooled into the final result by the random-effect model, generic inverse variance method.
RESULTS
RESULTS
A total of 8,861 articles were identified. After two rounds of independent review by three investigators, we included six cohort studies that met the eligibility criteria in the meta-analysis. The risk of dementia was significantly higher among psoriatic patients than in those without psoriasis with a pooled risk ratio of 1.16 (95% CI, 1.04-1.30; I2 95%). A funnel plot was relatively symmetric and was not suggestive of the presence of publication bias.
LIMITATIONS
CONCLUSIONS
Limited accuracy of diagnosis of psoriasis and dementia as four included studies were coding-based studies, and high statistical heterogeneity among studies.
CONCLUSION
CONCLUSIONS
This systematic review and meta-analysis indicates that psoriatic patients have a significantly elevated risk of developing dementia.
Identifiants
pubmed: 33666046
pii: IJDVL_732_19
doi: 10.25259/IJDVL_732_19
doi:
pii:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
364-370Références
Pink J, O'Brien J, Robinson L, Longson D, Guideline Committee,. Dementia: Assessment, management and support: Summary of updated NICE guidance. BMJ. 2018; 361:k2438
doi: 10.1136/bmj.k2438
pubmed: 29925626
Elahi FM, Miller BL,. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol. 2017; 13:457-76
doi: 10.1038/nrneurol.2017.96
pubmed: 28708131
van der Flier WM, Scheltens P,. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatr. 2005; 76: (Suppl 5)v2
doi: 10.1136/jnnp.2005.082867
pubmed: 16291918
Chen JH, Lin KP, Chen YC,. Risk factors for dementia. J Formos Med Assoc. 2009; 108:754-64
doi: 10.1016/S0929-6646(09)60402-2
Koyama A, O'Brien J, Weuve J, Blacker D, Metti AL, Yaffe K,. The role of peripheral inflammatory markers in dementia and Alzheimer's disease: A meta-analysis. J Gerontol A Biol Sci Med Sci. 2013; 68:433-40
doi: 10.1093/gerona/gls187
pubmed: 22982688
Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, et al. Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology. 2007; 68:1902-8
doi: 10.1212/01.wnl.0000263217.36439.da
pubmed: 17536046
Dogra S, Mahajan R,. Psoriasis: Epidemiology, clinical features, comorbidities, and clinical scoring. Indian Dermatol Online J. 2016; 7:471-80
doi: 10.4103/2229-5178.193906
pubmed: 27990381
Oliveira Mde F, Rocha Bde O, Duarte GV,. Psoriasis: Classical and emerging comorbidities. An Bras Dermatol. 2015; 90:9-20
doi: 10.1590/abd1806-4841.20153038
pubmed: 25672294
Huang KL, Yeh CC, Wu SI, Huang KY, Yang YH, Kuo TY, et al. Risk of dementia among individuals with psoriasis: A nationwide population-based cohort study in Taiwan. J Clin Psychiatry. 2019; 80:
doi: 10.4088/JCP.18m12462
Lee JH, Lee SH, Han K, Kim M,. Alzheimer's disease risk in patients with psoriasis: A nationwide population-based cohort study. J Eur Acad Dermatol Venereol. 2019; 33:22
doi: 10.1111/jdv.15783
pubmed: 31287593
Li X, Sundquist J, Zöller B, Sundquist K,. Dementia and Alzheimer's disease risks in patients with autoimmune disorders. Geriatr Gerontol Int. 2018; 18:1350-5
doi: 10.1111/ggi.13488
pubmed: 30044040
Wotton CJ, Goldacre MJ,. Associations between specific autoimmune diseases and subsequent dementia: Retrospective record-linkage cohort study, UK. J Epidemiol Community Health. 2017; 71:576-83
doi: 10.1136/jech-2016-207809
pubmed: 28249989
Dregan A, Chowienczyk P, Gulliford MC,. Are inflammation and related therapy associated with all-cause dementia in a primary care population?. J Alzheimers Dis. 2015; 46:1039-47
doi: 10.3233/JAD-150171
pubmed: 26402631
Pezzolo E, Mutlu U, Vernooij MW, Dowlatshahi EA, Gisondi P, Girolomoni G, et al. Psoriasis is not associated with cognition, brain imaging markers and risk of dementia: The rotterdam study. J Am Acad Dermatol. 2018;
doi: 10.1016/j.jaad.2018.07.046
pubmed: 30092331
Wells G, Shea B, O'Connell D, Peterson j, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. 2000;
DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-88
doi: 10.1016/0197-2456(86)90046-2
Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557-60
doi: 10.1136/bmj.327.7414.557
pubmed: 12958120
Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R,. Brain-derived neurotrophic factor: A bridge between inflammation and neuroplasticity. Front Cell Neurosci. 2014; 8:430
doi: 10.3389/fncel.2014.00430
pubmed: 25565964
Botterill JJ, Brymer KJ, Caruncho HJ, Kalynchuk LE,. Aberrant hippocampal neurogenesis after limbic kindling: Relationship to BDNF and hippocampal-dependent memory. Epilepsy Behav. 2015; 47:83-92
doi: 10.1016/j.yebeh.2015.04.046
pubmed: 25976182
Brunoni AR, Lotufo PA, Sabbag C, Goulart AC, Santos IS, Benseñor IM,. Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients. Braz J Med Biol Res. 2015; 48:711-4
doi: 10.1590/1414-431x20154574
pubmed: 26200230
Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G,. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol. 2013; 9:106-18
doi: 10.1038/nrneurol.2012.26310.1038/nrneurol.2013.32
pubmed: 23296339
Campalani E, Allen MH, Fairhurst D, Young HS, Mendonca CO, Burden AD, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol. 2006; 154:345-52
doi: 10.1111/j.1365-2133.2005.06950.x
pubmed: 16433808
in't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM,. Antihypertensive drugs and incidence of dementia: The rotterdam study. Neurobiol Aging. 2001; 22:407-12
doi: 10.1016/S0197-4580(00)00241-4
Judge A, Garriga C, Arden NK, Lovestone S, Prieto-Alhambra D, Cooper C, et al. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dement (N Y). 2017; 3:612-21
doi: 10.1016/j.trci.2017.10.002
pubmed: 29201995